

Edgar Filing: HALSEY DRUG CO INC/NEW - Form NT 10-Q

HALSEY DRUG CO INC/NEW  
Form NT 10-Q  
May 15, 2003

U.S. SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

Commission File  
Number (1-10113)

FORM 12b-25

NOTIFICATION OF LATE FILING

(Check One):  Form 10-K  Form 11-K  Form 20-F  Form 10-Q  Form N-SAR

For Period Ended: March 31, 2003  
-----

Transition Report on Form 10-K  Transition Report on Form 10-Q  
 Transition Report on Form 20-F  Transition Report on Form N-SAR  
 Transition Report on Form 11-K

For the Transition Period Ended: \_\_\_\_\_

Nothing in this Form shall be construed to imply that the Commission has  
verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify  
the Item(s) to which the notification  
relates: \_\_\_\_\_  
\_\_\_\_\_

PART I  
REGISTRANT INFORMATION

Full Name of Registrant HALSEY DRUG CO., INC.  
-----

Former Name if Applicable

Address of Principal Executive Office (Street and Number)

695 No. Perryville Road  
\_\_\_\_\_

City, State and Zip Code

Rockford , Illinois 61107  
\_\_\_\_\_

Edgar Filing: HALSEY DRUG CO INC/NEW - Form NT 10-Q

PART II  
RULE 12b-25(b) and (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

- (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
- (b) The subject annual report or semi-annual report, transition report on Form 10-K, 11-K or Form N-SAR, or portion thereof will be filed on or before the 15th calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and
- (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III  
NARRATIVE

State below in reasonable detail the reasons why the Form 10-K, 11-K, 20-F, 10-Q, N-SAR or the transition report portion thereof could not be filed within the prescribed time period.

On March 31, 2003, the Company applied for an extension of time to file its Form 10-K for the year ended December 31, 2002. The Company completed and filed its Form 10-K on May 9, 2003. The delay in the filing of the Form 10-K delayed the availability of financial information required to complete and file Form 10-Q for the fiscal quarter ended March 31, 2003. The Management anticipates the preparation and filing of Company's Form 10-Q for the fiscal quarter ended March 31, 2003 on or before the 5th calendar day following its prescribed due date.

PART IV  
OTHER INFORMATION

- (1) Name and telephone number of person to contact in regard to this notification:

Peter Clemens, Chief Financial Officer	(815)	399-2060
-----		
(Name)	(Area Code)	(Telephone Number)

- (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the

Investment Company Act of 1940 during the  Yes  No

Edgar Filing: HALSEY DRUG CO INC/NEW - Form NT 10-Q

preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, please identify report(s).

- (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? [X] Yes No [ ]

If so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

HALSEY DRUG CO., INC.

-----  
(Name of Registrant as Specified in Charter)

Has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 15, 2003

By: /s/ Peter Clemens

-----  
Peter Clemens, Vice President  
and Chief Financial Officer